MediWound Ltd.
This article was originally published in Start Up
Executive Summary
The first step in treating serious burns is to remove the burned layer of skin, or eschar. MediWound is developing a minimally invasive enzymatic alternative to the current gold standard: surgical excision. Its Debrase Gel Dressing, derived from pineapple plants, is highly selective for necrotic tissue. When topically applied to the burn site, it quickly digests and removes the eschar, leaving a clean wound bed.
You may also be interested in...
Wound Care: Medtech's New Billion Dollar Product Market
For some time now, investors have hated wound care. They've been scarred by past failures, most famously, the simultaneous bankruptcies in 2002 of Advanced Tissue Sciences and Organogenesis, two tissue-engineering companies targeting chronic wounds. "Show me one success," VCs tell start-ups seeking funding. Well, now there is one. Kinetic Concepts is pulling in a billion dollars in revenues from a single product in the advanced wound care market. Is it time for VCs to love advanced wound care? Five new device start-ups hope so. Three are developing therapeutic devices for chronic wounds and two are beginning in acute wound care, an emerging surgical market. (A Reprint of "Advanced Wound Care: The Device Industry's Billion Dollar Product Market," appearing in START-UP, November 2007.
In Brief February 2007
A short summary of recent clinical and market developments in the medical device industry.
FDA Gene Therapy Office Chief Prefers Flexibility With Accelerated Approval Confirmatory Trials
Ideally, the studies would be underway at the time of approval, as the US FDA’s new authority allows, but Office of Therapeutic Products Director Nicole Verdun sys there will be exceptions.